ketoconazole [Ligand Id: 2568] activity data from GtoPdb and ChEMBL

Click here for a description of the charts and data table

Please tell us if you are using this feature and what you think!

ChEMBL ligand: CHEMBL157101 (Daktarin gold, Daktarin intensiv, Dandrazol, Dandrid, Extina, J02AB02, Ketoconazol, Ketoconazole, Ketoconazole hra, Ketoconazolum, Ketopine, Ketosidin, Ketozole, Nizoral, Nizoral a-d, Nizoral anti-dandruff, Nizorelle, NSC-317629, Panfungol, R 41,400, R-41400, Xolegel)
  • CYP27B1/25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial in Human [ChEMBL: CHEMBL5993] [GtoPdb: 1370] [UniProtKB: O15528]
  • CYP27B1/25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial in Mouse [ChEMBL: CHEMBL3329080] [GtoPdb: 1370] [UniProtKB: O35084]
There should be some charts here, you may need to enable JavaScript!
  • α1A-adrenoceptor/Alpha-1a adrenergic receptor in Rat [ChEMBL: CHEMBL319] [GtoPdb: 22] [UniProtKB: P43140]
There should be some charts here, you may need to enable JavaScript!
  • α1B-adrenoceptor/Alpha-1b adrenergic receptor in Rat [ChEMBL: CHEMBL315] [GtoPdb: 23] [UniProtKB: P15823]
There should be some charts here, you may need to enable JavaScript!
  • α2A-adrenoceptor/Alpha-2a adrenergic receptor in Human [ChEMBL: CHEMBL1867] [GtoPdb: 25] [UniProtKB: P08913]
There should be some charts here, you may need to enable JavaScript!
  • α2B-adrenoceptor/Alpha-2b adrenergic receptor in Human [ChEMBL: CHEMBL1942] [GtoPdb: 26] [UniProtKB: P18089]
There should be some charts here, you may need to enable JavaScript!
  • Arachidonate 15-lipoxygenase in Rabbit [ChEMBL: CHEMBL4358] [UniProtKB: P12530]
There should be some charts here, you may need to enable JavaScript!
  • 5-LOX/Arachidonate 5-lipoxygenase in Rat [ChEMBL: CHEMBL312] [GtoPdb: 1385] [UniProtKB: P12527]
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
  • δ receptor/Delta opioid receptor in Human [ChEMBL: CHEMBL236] [GtoPdb: 317] [UniProtKB: P41143]
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
  • GnRH1 receptor/Gonadotropin-releasing hormone receptor in Rat [ChEMBL: CHEMBL3066] [GtoPdb: 256] [UniProtKB: P30969]
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
  • H2 receptor/Histamine H2 receptor in Human [ChEMBL: CHEMBL1941] [GtoPdb: 263] [UniProtKB: P25021]
There should be some charts here, you may need to enable JavaScript!
  • indoleamine 2,3-dioxygenase 1/Indoleamine 2,3-dioxygenase in Human [ChEMBL: CHEMBL4685] [GtoPdb: 2829] [UniProtKB: P14902]
There should be some charts here, you may need to enable JavaScript!
  • M2 receptor/Muscarinic acetylcholine receptor M2 in Human [ChEMBL: CHEMBL211] [GtoPdb: 14] [UniProtKB: P08172]
There should be some charts here, you may need to enable JavaScript!
  • NK2 receptor/Neurokinin 2 receptor in Human [ChEMBL: CHEMBL2327] [GtoPdb: 361] [UniProtKB: P21452]
There should be some charts here, you may need to enable JavaScript!
  • NET/Norepinephrine transporter in Human [ChEMBL: CHEMBL222] [GtoPdb: 926] [UniProtKB: P23975]
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
  • 5-HT1B receptor/Serotonin 1b (5-HT1b) receptor in Rat [ChEMBL: CHEMBL3459] [GtoPdb: 2] [UniProtKB: P28564]
There should be some charts here, you may need to enable JavaScript!
  • SERT/Serotonin transporter in Human [ChEMBL: CHEMBL228] [GtoPdb: 928] [UniProtKB: P31645]
There should be some charts here, you may need to enable JavaScript!
  • Organic cation transporter 1/Solute carrier family 22 member 1 in Human [ChEMBL: CHEMBL5685] [GtoPdb: 1019] [UniProtKB: O15245]
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
  • Cav1.2/Voltage-gated L-type calcium channel alpha-1C subunit in Rat [ChEMBL: CHEMBL3762] [GtoPdb: 529] [UniProtKB: P22002]
There should be some charts here, you may need to enable JavaScript!
  • Kv1.8 in Human [GtoPdb: 545] [UniProtKB: Q16322]
There should be some charts here, you may need to enable JavaScript!
DB Assay description Assay Type Standard value Standard parameter Original value Original units Original parameter Reference
CYP27B1/25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5993] [GtoPdb: 1370] [UniProtKB: O15528]
ChEMBL Inhibition of human CYP27B1 expressed in Escherichia coli assessed as reduction in hydrolase activity incubated for 25 mins using Adx, AdR and 1,25(OH)2D3 B 6.47 pIC50 340 nM IC50 Bioorg Med Chem (2017) 25: 5629-5636 [PMID:28886997]
CYP27B1/25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3329080] [GtoPdb: 1370] [UniProtKB: O35084]
ChEMBL Inhibition of mouse CYP27B1 using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method B 7.24 pKi 58 nM Ki J Med Chem (2014) 57: 7702-7715 [PMID:25148392]
ChEMBL Inhibition of mouse CYP27B1 by cell-free assay B 7.24 pKi 58 nM Ki Eur J Med Chem (2014) 87: 39-51 [PMID:25240094]
ChEMBL Inhibition of mouse CYP27B1 using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method B 6.44 pIC50 360 nM IC50 J Med Chem (2014) 57: 7702-7715 [PMID:25148392]
ChEMBL Inhibition of mouse CYP27B1 by cell-free assay B 6.44 pIC50 360 nM IC50 Eur J Med Chem (2014) 87: 39-51 [PMID:25240094]
α1A-adrenoceptor/Alpha-1a adrenergic receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL319] [GtoPdb: 22] [UniProtKB: P43140]
ChEMBL DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) B 4.84 pKi 14462 nM Ki DrugMatrix in vitro pharmacology data
ChEMBL DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) B 4.45 pIC50 35729 nM IC50 DrugMatrix in vitro pharmacology data
α1B-adrenoceptor/Alpha-1b adrenergic receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL315] [GtoPdb: 23] [UniProtKB: P15823]
ChEMBL DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) B 4.9 pKi 12683 nM Ki DrugMatrix in vitro pharmacology data
ChEMBL DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) B 4.64 pIC50 22910 nM IC50 DrugMatrix in vitro pharmacology data
α2A-adrenoceptor/Alpha-2a adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1867] [GtoPdb: 25] [UniProtKB: P08913]
ChEMBL DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) B 5.13 pKi 7419 nM Ki DrugMatrix in vitro pharmacology data
ChEMBL DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) B 4.7 pIC50 19783 nM IC50 DrugMatrix in vitro pharmacology data
α2B-adrenoceptor/Alpha-2b adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1942] [GtoPdb: 26] [UniProtKB: P18089]
ChEMBL DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) B 5.08 pKi 8239 nM Ki DrugMatrix in vitro pharmacology data
ChEMBL DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) B 4.74 pIC50 18047 nM IC50 DrugMatrix in vitro pharmacology data
Arachidonate 15-lipoxygenase in Rabbit (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4358] [UniProtKB: P12530]
ChEMBL DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) B 5.27 pIC50 5425 nM IC50 DrugMatrix in vitro pharmacology data
5-LOX/Arachidonate 5-lipoxygenase in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL312] [GtoPdb: 1385] [UniProtKB: P12527]
ChEMBL Inhibitory activity against 5-lipoxygenase of RBL-1 cell line B 4.6 pIC50 >25000 nM IC50 J Med Chem (1992) 35: 3148-3155 [PMID:1507204]
ABCB11/Bile salt export pump in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL6020] [GtoPdb: 778] [UniProtKB: O95342]
ChEMBL TP_TRANSPORTER: increase in dihydrofluorescein intracellular accumulation (dihydrofluorescein: 1 uM) in SK-E2 cells (expressing BSEP) F 4.18 pIC50 65400 nM IC50 Pharm Res (2003) 20: 537-544 [PMID:12739759]
ChEMBL Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake B 5.54 pIC50 2900 nM IC50 Drug Metab Dispos (2012) 40: 130-138 [PMID:21965623]
ABCB11/Bile salt export pump in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2073674] [GtoPdb: 778] [UniProtKB: O70127]
ChEMBL Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake B 4.81 pIC50 15600 nM IC50 Drug Metab Dispos (2012) 40: 130-138 [PMID:21965623]
CYP11A1/Cytochrome P450 11A1 in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5246] [GtoPdb: 1358] [UniProtKB: P14137]
ChEMBL Inhibition of cholesterol side chain cleavage cytochrome P450 B 5.27 pIC50 5400 nM IC50 J Med Chem (1992) 35: 2818-2825 [PMID:1495014]
ChEMBL Inhibition of cholesterol side chain cleavage cytochrome P450 B 5.91 pIC50 1240 nM IC50 J Med Chem (1992) 35: 2818-2825 [PMID:1495014]
CYP11B1/Cytochrome P450 11B1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1908] [GtoPdb: 1359] [UniProtKB: P15538]
ChEMBL Inhibitory concentration against human cytochrome P450 11B1 expressed in fission yeast, incubated with [14C]deoxycorticosterone B 6.65 pIC50 224 nM IC50 J Med Chem (2005) 48: 6632-6642 [PMID:16220979]
ChEMBL Inhibition of human CYP11B1 expressed in V79 11B1 cells B 6.65 pIC50 224 nM IC50 J Med Chem (2006) 49: 2222-2231 [PMID:16570918]
ChEMBL In vitro inhibitory concentration against human CYP11B1 expressed in V79 MZh hamster fibroblasts incubated with 100 nM of substrate deoxy-corticosterone in presence of the compound B 6.65 pIC50 224 nM IC50 J Med Chem (2005) 48: 1563-1575 [PMID:15743198]
ChEMBL Inhibition Assay: V79 MZh11B1 and V79 MZh 11B2 cells (8˙10^5 cells per well) were grown to confluency on 24-well cell culture plates with 1.9 cm^2 culture area per well (Nunc, Roskilde, Denmark). Before the test, the DMEM culture medium present was removed, and 450 μl of fresh DMEM with inhibitor was added for at least three concentrations to each well to determine the IC50. After preincubation (60 min, 37 °C.), the reaction was started by adding 50 μl of DMEM with 2.5 μl of solution of the substrate 11-deoxycorticosterone (20 μM, containing 1.25 nCi of [4-14C]11-deoxycorticosterone in ethanol). Thereafter, the plate was stored at 37 °C. and 5% CO2 in a CO2 incubator. The V79 MZh 11B1 cells were incubated for 120 min, and the V79 MZh 11B2 cells were incubated for 40 min. Controls without inhibitor were treated in the same way. The enzyme reactions were quenched by extracting the supernatant with 500 μl of EtOAc. The samples were centrifuged (10,000 g, 2 min), the solvent was removed and evaporated. The residue was taken up in 10 μl of chloroform and analyzed by HPTLC (see below). B 6.65 pIC50 224 nM IC50 US-9271963-B2. Selective inhibitors of human corticosteroid synthases (2016)
ChEMBL Inhibition Assay: V79 MZh11B1 and V79 MZh 11B2 cells (8˙10^5 cells per well) were grown to confluency on 24-well cell culture plates with 1.9 cm^2 culture area per well (Nunc, Roskilde, Denmark). Before the test, the DMEM culture medium present was removed, and 450 μl of fresh DMEM with inhibitor was added for at least three concentrations to each well to determine the IC50. After preincubation (60 min, 37 °C.), the reaction was started by adding 50 μl of DMEM with 2.5 μl of solution of the substrate 11-deoxycorticosterone (20 μM, containing 1.25 nCi of [4-14C]11-deoxycorticosterone in ethanol). Thereafter, the plate was stored at 37 °C. and 5% CO2 in a CO2 incubator. The V79 MZh 11B1 cells were incubated for 120 min, and the V79 MZh 11B2 cells were incubated for 40 min. Controls without inhibitor were treated in the same way. The enzyme reactions were quenched by extracting the supernatant with 500 μl of EtOAc. The samples were centrifuged (10,000 g, 2 min), the solvent was removed and evaporated. The residue was taken up in 10 μl of chloroform and analyzed by HPTLC (see below). B 6.65 pIC50 224 nM IC50 US-9271963-B2. Selective inhibitors of human corticosteroid synthases (2016)
ChEMBL Cellular Inhibition Assay: V79MZ cells expressing human CYP11B1 and human CYP11B2 genes, respectively, were grown on 24-well cell culture plates (8×10^5 cells per well) with 1.9 cm^2 culture area per well in 1 ml DMEM culture medium until confluence. Before testing, the DMEM culture medium was removed and 450 μl of fresh DMEM, containing the inhibitor in at least three different concentrations for determining the IC50 value, was added to each well. Every value was determined at least three times. After a pre-incubation step of 60 min at 37° C., the reaction was started by the addition of 50 μl of DMEM containing the substrate 11-deoxycorticosterone (containing 0.15 μCi of [1,2-3H] 11-deoxycorticosterone, dissolved in ethanol, final concentration 100 nM). The V79MZh11B1 cells were incubated for 25 min, the V79MZh11B2 cells were incubated for 50 min. Controls were treated in the same way without inhibitors. The maximum DMSO concentration in each well was 1%. Enzyme reactions were stopped by extracting the supernatant with 500 μl ethyl acetate. Samples were centrifuged (10000×g, 2 min), and the solvent was pipetted into fresh cups. The solvent was evaporated and the steroids were redissolved in 40 μl of methanol and analyzed by HPLC using radioflow detection (Ehmer et al. J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179 and Denner et al. Endocr. Res. 1995, 21, 443-448). B 6.9 pIC50 127 nM IC50 US-9394290-B2. Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases (2016)
ChEMBL Inhibition of human CYP11B1 expressed in hamster V79MZh11B1 cells B 6.9 pIC50 127 nM IC50 J Med Chem (2008) 51: 5009-5018 [PMID:18672868]
ChEMBL Inhibition of human CYP11B1 expressed in hamster V79MZh cells B 6.9 pIC50 127 nM IC50 J Med Chem (2010) 53: 5049-5053 [PMID:20550118]
ChEMBL Inhibition of human CYP11B1 expressed in hamster V79MZ cells using 11-deoxycorticosterone substrate B 6.9 pIC50 127 nM IC50 ACS Med Chem Lett (2011) 2: 2-6 [PMID:24900247]
ChEMBL Inhibition of human CYP11B1 expressed in hamster V79 MZ cells using [3H] 11 deoxycorticosterone as substrate by HPLC radioflow detector B 6.9 pIC50 127 nM IC50 ACS Med Chem Lett (2011) 2: 559-564 [PMID:24900349]
ChEMBL Inhibition of recombinant CYP11B1 (unknown origin) overexpressed in human AD293 cells assessed as reduction in cortisol formation preincubated for 60 mins followed by addition of 11-deoxycortisol as substrate measured after 12 hrs by LC-MS/MS analysis B 6.94 pIC50 116 nM IC50 Bioorg Med Chem Lett (2016) 26: 5825-5829 [PMID:27789139]
Cytochrome P450 11B1 in Bovine (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2927] [UniProtKB: P15150]
ChEMBL Inhibition of Corticoid 11-beta-hydroxylase cytochrome P450 B 6.22 pIC50 608 nM IC50 J Med Chem (1992) 35: 2818-2825 [PMID:1495014]
ChEMBL Inhibition of Corticoid 11-beta-hydroxylase cytochrome P450 B 6.82 pIC50 152 nM IC50 J Med Chem (1992) 35: 2818-2825 [PMID:1495014]
CYP11B2/Cytochrome P450 11B2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2722] [GtoPdb: 1360] [UniProtKB: P19099]
ChEMBL Inhibition of human aldosterone synthase expressed in yeast cells B 5.46 pIC50 3500 nM IC50 J Med Chem (2014) 57: 5011-5022 [PMID:24422519]
ChEMBL Inhibition of human aldosterone synthase expressed in V79 MZ cells B 6.19 pIC50 650 nM IC50 J Med Chem (2014) 57: 5011-5022 [PMID:24422519]
ChEMBL Inhibition Assay: V79 MZh11B1 and V79 MZh 11B2 cells (8˙10^5 cells per well) were grown to confluency on 24-well cell culture plates with 1.9 cm^2 culture area per well (Nunc, Roskilde, Denmark). Before the test, the DMEM culture medium present was removed, and 450 μl of fresh DMEM with inhibitor was added for at least three concentrations to each well to determine the IC50. After preincubation (60 min, 37 °C.), the reaction was started by adding 50 μl of DMEM with 2.5 μl of solution of the substrate 11-deoxycorticosterone (20 μM, containing 1.25 nCi of [4-14C]11-deoxycorticosterone in ethanol). Thereafter, the plate was stored at 37 °C. and 5% CO2 in a CO2 incubator. The V79 MZh 11B1 cells were incubated for 120 min, and the V79 MZh 11B2 cells were incubated for 40 min. Controls without inhibitor were treated in the same way. The enzyme reactions were quenched by extracting the supernatant with 500 μl of EtOAc. The samples were centrifuged (10,000 g, 2 min), the solvent was removed and evaporated. The residue was taken up in 10 μl of chloroform and analyzed by HPTLC (see below). B 7.09 pIC50 81 nM IC50 US-9271963-B2. Selective inhibitors of human corticosteroid synthases (2016)
ChEMBL Inhibition Assay: V79 MZh11B1 and V79 MZh 11B2 cells (8˙10^5 cells per well) were grown to confluency on 24-well cell culture plates with 1.9 cm^2 culture area per well (Nunc, Roskilde, Denmark). Before the test, the DMEM culture medium present was removed, and 450 μl of fresh DMEM with inhibitor was added for at least three concentrations to each well to determine the IC50. After preincubation (60 min, 37 °C.), the reaction was started by adding 50 μl of DMEM with 2.5 μl of solution of the substrate 11-deoxycorticosterone (20 μM, containing 1.25 nCi of [4-14C]11-deoxycorticosterone in ethanol). Thereafter, the plate was stored at 37 °C. and 5% CO2 in a CO2 incubator. The V79 MZh 11B1 cells were incubated for 120 min, and the V79 MZh 11B2 cells were incubated for 40 min. Controls without inhibitor were treated in the same way. The enzyme reactions were quenched by extracting the supernatant with 500 μl of EtOAc. The samples were centrifuged (10,000 g, 2 min), the solvent was removed and evaporated. The residue was taken up in 10 μl of chloroform and analyzed by HPTLC (see below). B 7.09 pIC50 81 nM IC50 US-9271963-B2. Selective inhibitors of human corticosteroid synthases (2016)
ChEMBL In vitro inhibitory concentration against human CYP11B2 expressed in V79MZh hamster fibroblasts incubated with 100 nM of substrate deoxy-corticosterone in presence of the compound B 7.09 pIC50 81 nM IC50 J Med Chem (2005) 48: 1563-1575 [PMID:15743198]
ChEMBL Inhibitory concentration against human cytochrome P450 11B2 expressed in fission yeast, incubated with [14C]deoxycorticosterone B 7.09 pIC50 81 nM IC50 J Med Chem (2005) 48: 6632-6642 [PMID:16220979]
ChEMBL Inhibition of human CYP11B2 expressed in V79 11B2 cells B 7.09 pIC50 81 nM IC50 J Med Chem (2006) 49: 2222-2231 [PMID:16570918]
ChEMBL Cellular Inhibition Assay: V79MZ cells expressing human CYP11B1 and human CYP11B2 genes, respectively, were grown on 24-well cell culture plates (8×10^5 cells per well) with 1.9 cm^2 culture area per well in 1 ml DMEM culture medium until confluence. Before testing, the DMEM culture medium was removed and 450 μl of fresh DMEM, containing the inhibitor in at least three different concentrations for determining the IC50 value, was added to each well. Every value was determined at least three times. After a pre-incubation step of 60 min at 37° C., the reaction was started by the addition of 50 μl of DMEM containing the substrate 11-deoxycorticosterone (containing 0.15 μCi of [1,2-3H] 11-deoxycorticosterone, dissolved in ethanol, final concentration 100 nM). The V79MZh11B1 cells were incubated for 25 min, the V79MZh11B2 cells were incubated for 50 min. Controls were treated in the same way without inhibitors. The maximum DMSO concentration in each well was 1%. Enzyme reactions were stopped by extracting the supernatant with 500 μl ethyl acetate. Samples were centrifuged (10000×g, 2 min), and the solvent was pipetted into fresh cups. The solvent was evaporated and the steroids were redissolved in 40 μl of methanol and analyzed by HPLC using radioflow detection (Ehmer et al. J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179 and Denner et al. Endocr. Res. 1995, 21, 443-448). B 7.17 pIC50 67 nM IC50 US-9394290-B2. Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases (2016)
ChEMBL Inhibition of human CYP11B2 expressed in hamster V79MZh11B2 cells B 7.17 pIC50 67 nM IC50 J Med Chem (2008) 51: 5009-5018 [PMID:18672868]
ChEMBL Inhibition of human CYP11B2 expressed in hamster V79MZh cells B 7.17 pIC50 67 nM IC50 J Med Chem (2010) 53: 5049-5053 [PMID:20550118]
ChEMBL Inhibition of human CYP11B2 expressed in hamster V79MZ cells using 11-deoxycorticosterone substrate B 7.17 pIC50 67 nM IC50 ACS Med Chem Lett (2011) 2: 2-6 [PMID:24900247]
ChEMBL Inhibition of human CYP11B2 expressed in hamster V79 MZ cells using [3H] 11 deoxycorticosterone as substrate by HPLC radioflow detector B 7.17 pIC50 67 nM IC50 ACS Med Chem Lett (2011) 2: 559-564 [PMID:24900349]
CYP17A1/Cytochrome P450 17A1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3522] [GtoPdb: 1361] [UniProtKB: P05093]
ChEMBL Binding affinity for Cytochrome P450 17A1 (17-alpha-hydroxypregnenolone Km=560 nM) B 7.42 pKi 38 nM Ki J Med Chem (1998) 41: 902-912 [PMID:9526564]
ChEMBL Inhibition of human CYP17 using 17alpha-hydroxypregnenolone substrate B 7.42 pKi 38 nM Ki J Med Chem (2015) 58: 2077-2087 [PMID:25591066]
ChEMBL Inhibition of human CYP17 expressed in Escherichia coli using progesterone as a substrate B 5.35 pIC50 4500 nM IC50 J Med Chem (2011) 54: 1613-1625 [PMID:21341743]
ChEMBL Inhibition of human CYP17 expressed in Escherichia coli using [3H]-progesterone substrate pre-incubated for 5 mins in presence of rat P450 reductase by HPLC method B 5.35 pIC50 4500 nM IC50 Eur J Med Chem (2015) 89: 106-114 [PMID:25462231]
ChEMBL Inhibition of Human P450 17 and NADPH-P450 reductase co-expressed in Escherichia coli with 25 uM progesterone B 5.55 pIC50 2800 nM IC50 J Med Chem (2000) 43: 4266-4277 [PMID:11063622]
ChEMBL Inhibition of human CYP17 expressed in Escherichia coli coexpressing NADPH-P450 reductase B 5.56 pIC50 2780 nM IC50 J Med Chem (2010) 53: 5049-5053 [PMID:20550118]
ChEMBL Inhibition of human CYP17 expressed in Escherichia coli co-expressed with NADPH-P450 reductase B 5.56 pIC50 2780 nM IC50 Bioorg Med Chem (2008) 16: 1992-2010 [PMID:18061460]
ChEMBL Inhibition of human recombinant CYP17 expressed in Escherichia coli B 5.56 pIC50 2780 nM IC50 J Med Chem (2008) 51: 5064-5074 [PMID:18672861]
ChEMBL Inhibition of human CYP17 expressed in Escherichia coli using progesterone as substrate B 5.56 pIC50 2780 nM IC50 Bioorg Med Chem Lett (2011) 21: 186-190 [PMID:21129965]
ChEMBL Inhibition of human CYP17 expressed in Escherichia coli coexpressed with cytochrome P450 reductase B 5.56 pIC50 2780 nM IC50 Bioorg Med Chem (2008) 16: 7715-7727 [PMID:18674917]
ChEMBL Inhibition of human recombinant CYP17 expressed in Escherichia coli pJL17/OR B 5.56 pIC50 2780 nM IC50 J Med Chem (2008) 51: 6138-6149 [PMID:18763754]
ChEMBL Inhibition of human CYP17 expressed in Escherichia coli F 5.56 pIC50 2780 nM IC50 J Med Chem (2008) 51: 8077-8087 [PMID:19049427]
ChEMBL Inhibition of human CYP17 expressed in Escherichia coli coexpressing NADPH-P450 reductase B 5.56 pIC50 2780 nM IC50 Eur J Med Chem (2009) 44: 2765-2775 [PMID:19211174]
ChEMBL Inhibition of human CYP17 expressed in Escherichia coli B 5.56 pIC50 2780 nM IC50 J Med Chem (2010) 53: 5347-5351 [PMID:20568782]
ChEMBL Inhibition of human CYP17 expressed in Escherichia coli B 5.56 pIC50 2780 nM IC50 J Med Chem (2010) 53: 5749-5758 [PMID:20684610]
ChEMBL Inhibition of human recombinant CYP17 expressed in Escherichia coli using progesterone as substrate B 5.56 pIC50 2780 nM IC50 Eur J Med Chem (2015) 90: 788-796 [PMID:25528333]
ChEMBL Inhibition of human CYP17 expressed in Escherichia coli using progesterone substrate B 5.56 pIC50 2780 nM IC50 J Med Chem (2011) 54: 2307-2319 [PMID:21384875]
ChEMBL Inhibition of human CYP17 expressed in Escherichia coli B 5.56 pIC50 2780 nM IC50 Bioorg Med Chem Lett (2008) 18: 267-273 [PMID:18024111]
ChEMBL In vitro inhibitory concentration against Cytochrome P450 17 expressed in Escherichia coli B 5.96 pIC50 1100 nM IC50 J Med Chem (2005) 48: 2972-2984 [PMID:15828836]
ChEMBL Inhibition of human testicular 17-alpha-hydroxylase B 6.04 pIC50 920 nM IC50 J Med Chem (1996) 39: 4335-4339 [PMID:8863811]
ChEMBL Inhibition of human testicular steroid 17-alpha-hydroxylase B 6.07 pIC50 860 nM IC50 J Med Chem (1996) 39: 4335-4339 [PMID:8863811]
ChEMBL Evaluated for the inhibitory activity towards Cytochrome P450 17 human enzyme using testicular microsome at 25 uM of substrate (progesterone) B 6.13 pIC50 740 nM IC50 J Med Chem (2000) 43: 4266-4277 [PMID:11063622]
ChEMBL Tested for inhibitory activity against Cytochrome P450 17 from human testicular microsomes B 6.13 pIC50 740 nM IC50 J Med Chem (2000) 43: 4437-4445 [PMID:11087568]
ChEMBL Inhibition of human testicular microsome Steroid 17-alpha-hydroxylase/17,20 lyase B 6.13 pIC50 740 nM IC50 J Med Chem (2001) 44: 672-680 [PMID:11262078]
ChEMBL Inhibition Assay: CYP17 activity was assayed according to the following procedure. Solutions of each test compound and isozyme inhibitor (ketoconazole) were separately prepared at concentrations of 2700, 540, 90, 18, 3, 0.6 and 0.1 uM by serial dilution with DMSO:ACN (50:50 v/v). The individual test compound and isozyme inhibitor solutions were then diluted 20-fold with deionized water (50:950 v/v) to concentrations of 135, 27, 4.5, 0.9, 0.15, 0.03 and 0.005 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture is 1%. Pooled rat testicular microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 1.25 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 2.5x. A stock solution of the substrate was prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution containing the substrate at 5 uM. B 6.4 pIC50 400 nM IC50 US-9150527-B2. Metalloenzyme inhibitor compounds (2015)
ChEMBL Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined. B 6.4 pIC50 400 nM IC50 US-8987315-B2. Metalloenzyme inhibitor compounds (2015)
ChEMBL Inhibition of recombinant CYP17 (unknown origin) overexpressed in human AD293 cells using [21-3H]17alpha-hydroxyl-pregenolone as substrate preincubated for 60 mins followed by substrate addition measured after 4 hrs by Topcount method B 7.03 pIC50 93 nM IC50 Bioorg Med Chem Lett (2016) 26: 5825-5829 [PMID:27789139]
ChEMBL CYP17 Inhibition Assay: A solution of 6.25 nmol of progesterone (in 5 μl of MeOH) was dissolved in 140 μl of phosphate buffer (0.05 M; pH 7.4; 1 mM MgCl2; 0.1 mM EDTA and 0.1 mM DTT) and preincubated for 5 min at 37 °C. together with 50 μl of NADPH-regenerating system (phosphate buffer with 10 mM NADP®, 100 mM glucose-6-phosphate and 2,5 units of glucose-6-phosphate dehydrogenase) and inhibitor (in 5 μl of DMSO). Control incubations were performed in parallel with 5 μl DMSO without inhibitor. The reaction was started by adding 50 μl of a membrane suspension diluted 1 to 5 in phosphate buffer (0.8 to 1 mg of protein per ml). After thoroughly mixing the components, the mixture was incubated at 37 °C. for 30 min. The reaction was quenched by adding 50 μl of 1 N HCl. The steroids were extracted with 1 ml of EtOAc. After a centrifugation step (5 min at 2,500 g), 900 μl of the organic phase was transferred into an Eppendorf vessel with 250 μl of the incubation buffer and 50 μl of 1 N HCl and again shaken. After the centrifugation, 800 μl of the organic phase was removed, placed into a new vessel and evaporated to dryness. The samples were dissolved in 50 μl of a water-methanol mixture (1:1) and analyzed by HPLC. B 7.09 pIC50 80.5 nM IC50 US-9271963-B2. Selective inhibitors of human corticosteroid synthases (2016)
ChEMBL Inhibition of human CYP17 using 17alpha-hydroxypregnenolone substrate B 7.11 pIC50 78 nM IC50 J Med Chem (2015) 58: 2077-2087 [PMID:25591066]
ChEMBL Inhibition of human testicular microsomal Cytochrome P450 17A1 B 7.11 pIC50 78 nM IC50 J Med Chem (1998) 41: 902-912 [PMID:9526564]
ChEMBL Inhibition of human testicular microsomal Cytochrome P450 17A1 B 7.11 pIC50 77 nM IC50 J Med Chem (1997) 40: 3297-3304 [PMID:9379450]
ChEMBL Inhibition of human recombinant CYP17 expressed in Escherichia coli coexpressing NADPH-P450 reductase B 7.14 pIC50 72 nM IC50 J Med Chem (2008) 51: 5009-5018 [PMID:18672868]
ChEMBL Ability to inhibit the Steroid 17-alpha-hydroxylase/17,20 lyase enzyme by 50%. B 7.19 pIC50 65 nM IC50 J Med Chem (1995) 38: 2463-2471 [PMID:7608911]
ChEMBL Tested for inhibition of human testicular Steroid 17-alpha-hydroxylase/17,20 lyase B 7.19 pIC50 65 nM IC50 J Med Chem (1995) 38: 4191-4197 [PMID:7473546]
ChEMBL Inhibition of 17-alpha-hydroxylase enzyme, cytochrome P450 17A1 of human testicular microsomes B 7.19 pIC50 65 nM IC50 J Med Chem (1996) 39: 3319-3323 [PMID:8765515]
ChEMBL Inhibition of recombinant CYP17 (unknown origin) overexpressed in human AD293 cells using [21-3H]17alpha-hydroxyl-pregenolone as substrate preincubated for 60 mins followed by substrate addition measured after 4 hrs by Topcount method B 7.32 pIC50 48 nM IC50 Bioorg Med Chem Lett (2016) 26: 5825-5829 [PMID:27789139]
ChEMBL Ability to inhibit the C17,20-lyase enzyme by 50% using 17-alpha-hydroxyprogesterone as substrate. B 7.59 pIC50 26 nM IC50 J Med Chem (1995) 38: 2463-2471 [PMID:7608911]
ChEMBL Inhibition of C17,20-lyase enzyme, cytochrome P450 17A1 in Human testicular microsomes B 7.59 pIC50 26 nM IC50 J Med Chem (1996) 39: 3319-3323 [PMID:8765515]
ChEMBL Tested for inhibition of human testicular C17,20-Lyase. B 7.59 pIC50 26 nM IC50 J Med Chem (1995) 38: 4191-4197 [PMID:7473546]
CYP17A1/Cytochrome P450 17A1 in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4430] [GtoPdb: 1361] [UniProtKB: P11715]
ChEMBL Tested for inhibitory activity against Cytochrome P450 17 from rat testicular microsomes B 4.17 pIC50 67000 nM IC50 J Med Chem (2000) 43: 4437-4445 [PMID:11087568]
ChEMBL Evaluated for the inhibitory activity towards Cytochrome P450 17 rat enzyme using testicular microsome at 25 uM of substrate (progesterone) B 4.17 pIC50 67000 nM IC50 J Med Chem (2000) 43: 4266-4277 [PMID:11063622]
ChEMBL Inhibition of rat testicular C17,20-Lyase B 4.96 pIC50 11000 nM IC50 J Med Chem (1995) 38: 4191-4197 [PMID:7473546]
ChEMBL Inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation B 4.96 pIC50 11000 nM IC50 J Med Chem (1990) 33: 2452-2455 [PMID:2391687]
ChEMBL Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation B 5.22 pIC50 6000 nM IC50 J Med Chem (1990) 33: 2452-2455 [PMID:2391687]
ChEMBL Inhibition of rat testicular Steroid 17-alpha-hydroxylase/17,20 lyase B 5.22 pIC50 6000 nM IC50 J Med Chem (1995) 38: 4191-4197 [PMID:7473546]
ChEMBL Inhibition of rat microsomal 17-alpha-hydroxylase component of P450-17alpha B 5.42 pIC50 3760 nM IC50 Bioorg Med Chem Lett (2006) 16: 4011-4015 [PMID:16750362]
ChEMBL Inhibition of rat testis 17-alpha-hydroxylase component of P450-17alpha B 5.42 pIC50 3760 nM IC50 Bioorg Med Chem Lett (2006) 16: 4752-4756 [PMID:16870430]
ChEMBL Inhibition of 17-alpha-hydroxylase activity of rat testicular microsomal P450-17alpha B 5.42 pIC50 3760 nM IC50 Bioorg Med Chem Lett (2009) 19: 4698-4701 [PMID:19608417]
ChEMBL Inhibition of 17-alpha-hydroxylase activity of rat testicular microsomal P450-17alpha B 5.58 pIC50 2660 nM IC50 Bioorg Med Chem Lett (2010) 20: 5345-5348 [PMID:20675132]
ChEMBL Inhibition of rat testis 17,20 lyase component of P450-17alpha B 5.78 pIC50 1660 nM IC50 Bioorg Med Chem Lett (2006) 16: 4752-4756 [PMID:16870430]
ChEMBL Inhibition of rat microsomal 17,20-lyase component of P450-17alpha B 5.78 pIC50 1660 nM IC50 Bioorg Med Chem Lett (2006) 16: 4011-4015 [PMID:16750362]
ChEMBL Inhibition of 17,20-lyase activity of rat testicular microsomal P450-17alpha B 5.78 pIC50 1660 nM IC50 Bioorg Med Chem Lett (2009) 19: 4698-4701 [PMID:19608417]
ChEMBL Inhibition of rat testicular microsomal Cytochrome P450 17A1 B 5.97 pIC50 1067 nM IC50 J Med Chem (1997) 40: 3297-3304 [PMID:9379450]
ChEMBL Inhibition of Wistar rat testicular C17,20-lyase using [3H]17-hydroxyprogesterone as substrate preincubated for 20 mins B 6.49 pIC50 320 nM IC50 Eur J Med Chem (2013) 70: 649-660 [PMID:24211641]
ChEMBL Inhibition of Wistar rat testicular C17,20-lyase assessed as androst-4-ene-3,17-dione formation using [3H]17-hydroxyprogesterone as substrate in presence of NADPH B 6.49 pIC50 320 nM IC50 Eur J Med Chem (2016) 120: 284-295 [PMID:27209562]
ChEMBL Inhibition of rat Cytochrome P450 17A1 B 6.68 pIC50 209 nM IC50 J Med Chem (1998) 41: 902-912 [PMID:9526564]
ChEMBL Inhibition of 17,20-lyase activity of rat testicular microsomal P450-17alpha B 6.69 pIC50 206 nM IC50 Bioorg Med Chem Lett (2010) 20: 5345-5348 [PMID:20675132]
CYP19A1/Cytochrome P450 19A1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1978] [GtoPdb: 1362] [UniProtKB: P11511]
ChEMBL Binding affinity was measured on Cytochrome P450 19A1 B 4.19 pKi 65000 nM Ki J Med Chem (1990) 33: 2933-2942 [PMID:2231592]
ChEMBL Inhibition of human recombinant aromatase assessed as conversion of O-dibenzylfluorescein benzyl ester substrate to fluorescein byproduct by fluorometric assay B 6.4 pKi 400 nM Ki Bioorg Med Chem Lett (2012) 22: 718-722 [PMID:22079757]
ChEMBL Inhibition of human recombinant aromatase assessed as conversion of O-dibenzylfluorescein benzyl ester substrate to fluorescein byproduct by fluorometric assay B 6.4 pKi 398.11 nM Ki Bioorg Med Chem Lett (2012) 22: 718-722 [PMID:22079757]
ChEMBL Inhibition of CYP19 in human placental microsomes B 4.3 pIC50 >50000 nM IC50 J Med Chem (2010) 53: 5049-5053 [PMID:20550118]
ChEMBL Inhibition of cytochrome P450 19A1 involved in steroid biosynthesis B 4.4 pIC50 39600 nM IC50 J Med Chem (1992) 35: 2818-2825 [PMID:1495014]
ChEMBL Inhibition of Cytochrome P450 19A1 in Human placental microsomes B 4.8 pIC50 16000 nM IC50 J Med Chem (1996) 39: 3319-3323 [PMID:8765515]
ChEMBL Inhibition of human aromatase by fluorometric assay B 5.52 pIC50 3000 nM IC50 Bioorg Med Chem (2008) 16: 8466-8470 [PMID:18778944]
ChEMBL Inhibition of CYP19 (unknown origin) using O-benzyl fluorescein benzyl ester substrate preincubated for 10 mins by fluorimetric analysis relative to control B 5.59 pIC50 2600 nM IC50 Bioorg Med Chem (2015) 23: 3472-3480 [PMID:25934226]
ChEMBL Inhibition of CYP19 B 5.62 pIC50 2400 nM IC50 J Nat Prod (2011) 74: 79-81 [PMID:21174408]
ChEMBL Inhibition of human recombinant aromatase expressed in baculovirus/insect cells using 7-methoxy-trifluoromethylcoumarin as substrate after 30 mins by fluorescence-based spectrophotometry B 5.89 pIC50 1300 nM IC50 Bioorg Med Chem (2012) 20: 2603-2613 [PMID:22444875]
ChEMBL Inhibition of human recombinant aromatase B 6.05 pIC50 900 nM IC50 J Nat Prod (2007) 70: 353-360 [PMID:17291041]
ChEMBL Inhibition of human recombinant aromatase B 6.1 pIC50 800 nM IC50 J Nat Prod (2008) 71: 1793-1799 [PMID:18939864]
ChEMBL Inhibition of human placental microsome CYP19 B 7.22 pIC50 60 nM IC50 Bioorg Med Chem Lett (2010) 20: 3050-3064 [PMID:20413308]
ChEMBL Inhibition of human placental CYP19 B 7.4 pIC50 40 nM IC50 J Med Chem (2006) 49: 2222-2231 [PMID:16570918]
CYP21A2/Cytochrome P450 21 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2759] [GtoPdb: 1364] [UniProtKB: P08686]
ChEMBL Inhibition of Progesterone 21-hydroxylase cytochrome P450 21 B 4.95 pIC50 11200 nM IC50 J Med Chem (1992) 35: 2818-2825 [PMID:1495014]
ChEMBL Inhibition of Progesterone 21-hydroxylase cytochrome P450 21 B 5.05 pIC50 9010 nM IC50 J Med Chem (1992) 35: 2818-2825 [PMID:1495014]
ChEMBL Inhibition of recombinant CYP21 (unknown origin) overexpressed in human AD293 cells assessed as reduction in 11-deoxycortisol formation preincubated for 60 mins followed by addition of 17-alpha-hydroxyprogesterone as substrate measured after 45 mins by LC-MS/MS analysis B 5.37 pIC50 4300 nM IC50 Bioorg Med Chem Lett (2016) 26: 5825-5829 [PMID:27789139]
CYP24A1/Cytochrome P450 24A1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4521] [GtoPdb: 1365] [UniProtKB: Q07973]
ChEMBL Inhibition of N-terminally MBP-fused human CYP24A1 by cell-free assay B 7.46 pKi 35 nM Ki Eur J Med Chem (2014) 87: 39-51 [PMID:25240094]
ChEMBL Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method B 7.48 pKi 33 nM Ki J Med Chem (2014) 57: 7702-7715 [PMID:25148392]
ChEMBL Inhibition of CYP24A1 expressed in CHO cells B 6.28 pIC50 520 nM IC50 Eur J Med Chem (2010) 45: 4427-4434 [PMID:20655626]
ChEMBL Inhibition of N-terminal MBP-tagged human CYP24A1 expressed in Escherichia coli assessed as reduction in hydrolase activity incubated for 25 mins using Adx, AdR and 1,25(OH)2D3 B 6.3 pIC50 500 nM IC50 Bioorg Med Chem (2017) 25: 5629-5636 [PMID:28886997]
ChEMBL Inhibition of MBP-tagged human CYP24A1 expressed Escherichia coli BL21-Gold(DE3) incubated for 25 mins in presence of Adx, AdR 1,25(OH)2D3 and NADPH by HPLC method B 6.3 pIC50 500 nM IC50 Bioorg Med Chem (2017) 25: 4076-4087 [PMID:28601511]
ChEMBL Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method B 6.33 pIC50 470 nM IC50 J Med Chem (2014) 57: 7702-7715 [PMID:25148392]
ChEMBL Inhibition of N-terminally MBP-fused human CYP24A1 by cell-free assay B 6.33 pIC50 470 nM IC50 Eur J Med Chem (2014) 87: 39-51 [PMID:25240094]
ChEMBL Inhibition of human CYP24 hydroxylase expressed in V79 cells B 6.51 pIC50 312 nM IC50 J Med Chem (2004) 47: 6854-6863 [PMID:15615534]
CYP24A1/Cytochrome P450 24A1 in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3748] [GtoPdb: 1365] [UniProtKB: Q09128]
ChEMBL Inhibitory activity against 25-hydroxyvitamin D3 24-hydroxylase of rat kidney mitochondria B 4.7 pIC50 20000 nM IC50 Bioorg Med Chem Lett (2004) 14: 5651-5654 [PMID:15482941]
ChEMBL Inhibition of CYP24A1 in rat kidney mitochondria B 4.7 pIC50 20000 nM IC50 Eur J Med Chem (2010) 45: 4427-4434 [PMID:20655626]
CYP2C19/Cytochrome P450 2C19 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3622] [GtoPdb: 1328] [UniProtKB: P33261]
ChEMBL Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined. B 4.72 pIC50 19000 nM IC50 US-8987315-B2. Metalloenzyme inhibitor compounds (2015)
ChEMBL Inhibition Assay: CYP17 activity was assayed according to the following procedure. Solutions of each test compound and isozyme inhibitor (ketoconazole) were separately prepared at concentrations of 2700, 540, 90, 18, 3, 0.6 and 0.1 uM by serial dilution with DMSO:ACN (50:50 v/v). The individual test compound and isozyme inhibitor solutions were then diluted 20-fold with deionized water (50:950 v/v) to concentrations of 135, 27, 4.5, 0.9, 0.15, 0.03 and 0.005 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture is 1%. Pooled rat testicular microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 1.25 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 2.5x. A stock solution of the substrate was prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution containing the substrate at 5 uM. B 4.72 pIC50 19000 nM IC50 US-9150527-B2. Metalloenzyme inhibitor compounds (2015)
CYP2C9/Cytochrome P450 2C9 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3397] [GtoPdb: 1326] [UniProtKB: P11712]
ChEMBL Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined. B 4.4 pIC50 40000 nM IC50 US-8987315-B2. Metalloenzyme inhibitor compounds (2015)
ChEMBL Inhibition Assay: CYP17 activity was assayed according to the following procedure. Solutions of each test compound and isozyme inhibitor (ketoconazole) were separately prepared at concentrations of 2700, 540, 90, 18, 3, 0.6 and 0.1 uM by serial dilution with DMSO:ACN (50:50 v/v). The individual test compound and isozyme inhibitor solutions were then diluted 20-fold with deionized water (50:950 v/v) to concentrations of 135, 27, 4.5, 0.9, 0.15, 0.03 and 0.005 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture is 1%. Pooled rat testicular microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 1.25 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 2.5x. A stock solution of the substrate was prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution containing the substrate at 5 uM. B 4.4 pIC50 40000 nM IC50 US-9150527-B2. Metalloenzyme inhibitor compounds (2015)
CYP3A4/Cytochrome P450 3A4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL340] [GtoPdb: 1337] [UniProtKB: P08684]
GtoPdb - - 7 pKi 100 nM Ki Br J Clin Pharmacol (2015) 80: 342-50 [PMID:25923589]
ChEMBL In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4). B 5.06 pIC50 8800 nM IC50 US-9144538-B2. Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin (2015)
ChEMBL null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C. B 5.06 pIC50 8800 nM IC50 US-9138393-B2. Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin (2015)
ChEMBL null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs. B 6.3 pIC50 500 nM IC50 US-9138393-B2. Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin (2015)
ChEMBL In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity. B 6.3 pIC50 500 nM IC50 US-9144538-B2. Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin (2015)
ChEMBL Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined. B 6.82 pIC50 150 nM IC50 US-8987315-B2. Metalloenzyme inhibitor compounds (2015)
ChEMBL Inhibition Assay: CYP17 activity was assayed according to the following procedure. Solutions of each test compound and isozyme inhibitor (ketoconazole) were separately prepared at concentrations of 2700, 540, 90, 18, 3, 0.6 and 0.1 uM by serial dilution with DMSO:ACN (50:50 v/v). The individual test compound and isozyme inhibitor solutions were then diluted 20-fold with deionized water (50:950 v/v) to concentrations of 135, 27, 4.5, 0.9, 0.15, 0.03 and 0.005 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture is 1%. Pooled rat testicular microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 1.25 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 2.5x. A stock solution of the substrate was prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution containing the substrate at 5 uM. B 6.82 pIC50 150 nM IC50 US-9150527-B2. Metalloenzyme inhibitor compounds (2015)
ChEMBL Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes B 7.24 pIC50 57 nM IC50 J Med Chem (2010) 53: 5049-5053 [PMID:20550118]
ChEMBL DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) B 7.8 pIC50 16 nM IC50 DrugMatrix in vitro pharmacology data
ChEMBL Fluorescent High Throughput P450 Assay: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5). Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. Concentration-response curves performed in duplicate for known inhibitors for each isoenzyme were tested in ever B 7.92 pIC50 12 nM IC50 US-9173935-B2. Phospholipid drug analogs (2015)
ChEMBL Fluorescent High Throughput P450 Assays: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5).Materials and Methods: Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. B 7.92 pIC50 12 nM IC50 US-9180183-B2. Phospholipid drug analogs (2015)
CYP3A5/Cytochrome P450 3A5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3019] [GtoPdb: 1338] [UniProtKB: P20815]
ChEMBL Fluorescent High Throughput P450 Assay: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5). Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. Concentration-response curves performed in duplicate for known inhibitors for each isoenzyme were tested in ever B 6.92 pIC50 120 nM IC50 US-9173935-B2. Phospholipid drug analogs (2015)
ChEMBL Fluorescent High Throughput P450 Assays: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5).Materials and Methods: Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. B 6.92 pIC50 120 nM IC50 US-9180183-B2. Phospholipid drug analogs (2015)
CYP51A1/Cytochrome P450 51 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3849] [GtoPdb: 1374] [UniProtKB: Q16850]
ChEMBL Binding affinity to human CYP51 B 5.1 pKd 8000 nM Kd Drug Metab Dispos (2007) 35: 493-500 [PMID:17194716]
ChEMBL Binding affinity to human His-tagged CYP51 expressed in Escherichia coli B 6.96 pKd 110 nM Kd Bioorg Med Chem (2008) 16: 209-221 [PMID:17964172]
ChEMBL Binding affinity to human CYP51 B 6.96 pKd 110 nM Kd Antimicrob Agents Chemother (2009) 53: 1157-1164 [PMID:19075057]
ChEMBL Inhibition of lanosterol 14-alpha-demethylase in hamster hepatic microsomes B 7.2 pKi 63.5 nM Ki J Med Chem (1993) 36: 2235-2237 [PMID:8340925]
ChEMBL Inhibition of lanosterol 14-alpha-demethylase in hamster hepatic microsomes B 7.61 pKi 24.5 nM Ki J Med Chem (1993) 36: 2235-2237 [PMID:8340925]
ChEMBL Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay B 6.72 pIC50 190 nM IC50 Drug Metab Dispos (2007) 35: 493-500 [PMID:17194716]
CYP51A1/Cytochrome P450 51 in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4981] [GtoPdb: 1374] [UniProtKB: Q64654]
ChEMBL Inhibition of lanosterol 14-alpha-demethylase of rat hepatic microsomes B 7.19 pKi 65 nM Ki J Med Chem (1993) 36: 2235-2237 [PMID:8340925]
ChEMBL Inhibition of lanosterol 14 alpha-demethylase cytochrome P450 51A B 6.92 pIC50 119 nM IC50 J Med Chem (1992) 35: 2818-2825 [PMID:1495014]
ChEMBL Inhibition of lanosterol 14 alpha-demethylase cytochrome P450 51A B 7.33 pIC50 47 nM IC50 J Med Chem (1992) 35: 2818-2825 [PMID:1495014]
CYP7A1/Cytochrome P450 7A1 in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2339] [GtoPdb: 1354] [UniProtKB: P18125]
ChEMBL Inhibition of cytochrome P450 Cholesterol 7-alpha-hydroxylase B 5.62 pIC50 2400 nM IC50 J Med Chem (1992) 35: 2818-2825 [PMID:1495014]
ChEMBL Inhibition of cytochrome P450 Cholesterol 7-alpha-hydroxylase B 6.71 pIC50 195 nM IC50 J Med Chem (1992) 35: 2818-2825 [PMID:1495014]
δ receptor/Delta opioid receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL236] [GtoPdb: 317] [UniProtKB: P41143]
ChEMBL DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) B 5.35 pKi 4511 nM Ki DrugMatrix in vitro pharmacology data
ChEMBL DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) B 4.89 pIC50 12797 nM IC50 DrugMatrix in vitro pharmacology data
DAT/Dopamine transporter in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL238] [GtoPdb: 927] [UniProtKB: Q01959]
ChEMBL DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) B 4.73 pKi 18685 nM Ki DrugMatrix in vitro pharmacology data
ChEMBL DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) B 4.63 pIC50 23517 nM IC50 DrugMatrix in vitro pharmacology data
GnRH1 receptor/Gonadotropin-releasing hormone receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3066] [GtoPdb: 256] [UniProtKB: P30969]
ChEMBL Dissociation constant was determined in vitro using rat pituitary membranes and [125I]leuprolide as radioligand, at concentration 3.16*10e-5 M B 6.09 pKd 811 nM Kd J Med Chem (1989) 32: 2036-2038 [PMID:2549244]
ChEMBL Dissociation constant was determined in vitro using rat pituitary membranes, at concentration 1.0*10e-5 M B 9.43 pKd 0.38 nM Kd J Med Chem (1989) 32: 2036-2038 [PMID:2549244]
ChEMBL Dissociation constant was determined in vitro using rat pituitary membranes and [125I]-leuprolide as radioligand, at concentration 3.16*10e-6 M B 9.66 pKd 0.22 nM Kd J Med Chem (1989) 32: 2036-2038 [PMID:2549244]
ChEMBL Binding affinity at LH-RH receptor in rat pituitary using [125I]leuprolide as radioligand B 5.7 pIC50 2000 nM IC50 J Med Chem (1989) 32: 2036-2038 [PMID:2549244]
Kv11.1/HERG in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL240] [GtoPdb: 572] [UniProtKB: Q12809]
ChEMBL Inhibition of human Potassium channel HERG expressed in mammalian cells B 5.72 pIC50 1905.46 nM IC50 Bioorg Med Chem Lett (2003) 13: 2773-2775 [PMID:12873512]
ChEMBL Inhibitory concentration against potassium channel HERG B 5.72 pIC50 1905.46 nM IC50 Bioorg Med Chem Lett (2005) 15: 2886-2890 [PMID:15911273]
ChEMBL Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique B 5.72 pIC50 1905.46 nM IC50 Bioorg Med Chem (2008) 16: 6252-6260 [PMID:18448342]
ChEMBL Inhibition of human ERG B 5.72 pIC50 1905.46 nM IC50 Eur J Med Chem (2011) 46: 618-630 [PMID:21185626]
ChEMBL Inhibition of human ERG channel B 5.72 pIC50 1900 nM IC50 J Med Chem (2009) 52: 4266-4276 [PMID:19534531]
ChEMBL Inhibition of human ERG channel B 5.72 pIC50 1900 nM IC50 J Med Chem (2009) 52: 4266-4276 [PMID:19534531]
H2 receptor/Histamine H2 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1941] [GtoPdb: 263] [UniProtKB: P25021]
ChEMBL DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) B 4.67 pKi 21507 nM Ki DrugMatrix in vitro pharmacology data
ChEMBL DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) B 4.66 pIC50 21872 nM IC50 DrugMatrix in vitro pharmacology data
indoleamine 2,3-dioxygenase 1/Indoleamine 2,3-dioxygenase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4685] [GtoPdb: 2829] [UniProtKB: P14902]
ChEMBL Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins by HPLC B 4.49 pIC50 32000 nM IC50 Eur J Med Chem (2014) 84: 284-301 [PMID:25036789]
ChEMBL Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins in presence of 0.01% Triton-X by HPLC B 4.6 pIC50 25000 nM IC50 Eur J Med Chem (2014) 84: 284-301 [PMID:25036789]
M2 receptor/Muscarinic acetylcholine receptor M2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL211] [GtoPdb: 14] [UniProtKB: P08172]
ChEMBL DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) B 5.03 pKi 9368 nM Ki DrugMatrix in vitro pharmacology data
ChEMBL DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) B 4.58 pIC50 26346 nM IC50 DrugMatrix in vitro pharmacology data
NK2 receptor/Neurokinin 2 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2327] [GtoPdb: 361] [UniProtKB: P21452]
ChEMBL DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) B 5.24 pKi 5748 nM Ki DrugMatrix in vitro pharmacology data
ChEMBL DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) B 4.76 pIC50 17243 nM IC50 DrugMatrix in vitro pharmacology data
NET/Norepinephrine transporter in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL222] [GtoPdb: 926] [UniProtKB: P23975]
ChEMBL DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) B 4.62 pKi 24003 nM Ki DrugMatrix in vitro pharmacology data
ChEMBL DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) B 4.62 pIC50 24203 nM IC50 DrugMatrix in vitro pharmacology data
ABCB1/P-glycoprotein 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4302] [GtoPdb: 768] [UniProtKB: P08183]
ChEMBL TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in MDR1-expressing LLC-PK1 cells F 4.6 pKi 24900 nM Ki Mol Pharmacol (2002) 61: 964-973 [PMID:11961113]
ChEMBL TP_TRANSPORTER: increase in Vinblastine intracellular accumulation in MDR1-expressing LLC-PK1 cells F 5.28 pKi 5270 nM Ki Mol Pharmacol (2002) 61: 964-973 [PMID:11961113]
ChEMBL High affinity constant at binding site of human P-Glycoprotein (P-gp) in two-affinity model B 5.92 pKi 1200 nM Ki J Med Chem (2002) 45: 5671-5686 [PMID:12477351]
ChEMBL TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells F 4.27 pIC50 53400 nM IC50 Biochem Biophys Res Commun (2001) 289: 580-585 [PMID:11716514]
ChEMBL TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells F 4.63 pIC50 23400 nM IC50 Biochem Biophys Res Commun (2001) 289: 580-585 [PMID:11716514]
ChEMBL Concentration required for 50% inhibition at binding site of human P-Glycoprotein (P-gp) in one-affinity model B 4.89 pIC50 13000 nM IC50 J Med Chem (2002) 45: 5671-5686 [PMID:12477351]
ChEMBL Inhibition of human recombinant MDR1 in cell membrane fraction preincubated for 5 mins measured after 40 mins by Pgp-Glo luciferase assay B 5.01 pIC50 9740 nM IC50 Bioorg Med Chem Lett (2015) 25: 297-301 [PMID:25499431]
ChEMBL TP_TRANSPORTER: inhibition of Daunorubicin transport in G185 cells F 5.25 pIC50 5600 nM IC50 Antimicrob Agents Chemother (2002) 46: 160-165 [PMID:11751127]
ChEMBL TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells F 5.25 pIC50 5600 nM IC50 Biochem Biophys Res Commun (2001) 289: 580-585 [PMID:11716514]
ChEMBL TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells F 5.32 pIC50 4800 nM IC50 J Med Chem (2003) 46: 1716-1725 [PMID:12699389]
ChEMBL Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay F 5.32 pIC50 4800 nM IC50 J Med Chem (2003) 46: 1716-1725 [PMID:12699389]
ChEMBL TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells F 5.92 pIC50 1200 nM IC50 Drug Metab Dispos (2000) 28: 655-660 [PMID:10820137]
ChEMBL Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC F 6 pIC50 1000 nM IC50 J Med Chem (2003) 46: 1716-1725 [PMID:12699389]
P-glycoprotein 1 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3467] [UniProtKB: P06795]
ChEMBL TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1b-expressing LLC-PK1 cells F 5.16 pKi 6930 nM Ki J Pharmacol Exp Ther (2002) 303: 323-332 [PMID:12235267]
ChEMBL Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay F 5.17 pIC50 6700 nM IC50 J Med Chem (2003) 46: 1716-1725 [PMID:12699389]
ChEMBL TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells F 5.17 pIC50 6700 nM IC50 J Med Chem (2003) 46: 1716-1725 [PMID:12699389]
ABCB1/P-glycoprotein 3 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2573] [GtoPdb: 768] [UniProtKB: P21447]
ChEMBL TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1a-expressing LLC-PK1 cells F 4.89 pKi 12800 nM Ki J Pharmacol Exp Ther (2002) 303: 323-332 [PMID:12235267]
ChEMBL Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay F 5.42 pIC50 3800 nM IC50 J Med Chem (2003) 46: 1716-1725 [PMID:12699389]
ChEMBL TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells F 5.42 pIC50 3800 nM IC50 J Med Chem (2003) 46: 1716-1725 [PMID:12699389]
Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364]
ChEMBL Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay F 4.9 pIC50 12589.25 nM IC50 Nat Chem Biol (2009) 5: 765-771 [PMID:19734910]
ChEMBL Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay F 5 pIC50 10000 nM IC50 Nat Chem Biol (2009) 5: 765-771 [PMID:19734910]
ChEMBL Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay F 5 pIC50 10000 nM IC50 Nat Chem Biol (2009) 5: 765-771 [PMID:19734910]
ChEMBL Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay F 5.1 pIC50 7943.28 nM IC50 Nat Chem Biol (2009) 5: 765-771 [PMID:19734910]
ChEMBL Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay F 5.1 pIC50 7943.28 nM IC50 Nat Chem Biol (2009) 5: 765-771 [PMID:19734910]
ChEMBL Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay F 5.1 pIC50 7943.28 nM IC50 Nat Chem Biol (2009) 5: 765-771 [PMID:19734910]
ChEMBL Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay F 5.1 pIC50 7943.28 nM IC50 Nat Chem Biol (2009) 5: 765-771 [PMID:19734910]
5-HT1B receptor/Serotonin 1b (5-HT1b) receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3459] [GtoPdb: 2] [UniProtKB: P28564]
ChEMBL DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) B 5.21 pKi 6154 nM Ki DrugMatrix in vitro pharmacology data
ChEMBL DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) B 4.87 pIC50 13539 nM IC50 DrugMatrix in vitro pharmacology data
SERT/Serotonin transporter in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL228] [GtoPdb: 928] [UniProtKB: P31645]
ChEMBL DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) B 6.55 pKi 282 nM Ki DrugMatrix in vitro pharmacology data
ChEMBL DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) B 6.27 pIC50 531 nM IC50 DrugMatrix in vitro pharmacology data
Organic cation transporter 1/Solute carrier family 22 member 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5685] [GtoPdb: 1019] [UniProtKB: O15245]
ChEMBL Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay B 5.59 pIC50 2600 nM IC50 J Med Chem (2017) 60: 2685-2696 [PMID:28230985]
CYP5A1/Thromboxane-A synthase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1835] [GtoPdb: 1353] [UniProtKB: P24557]
ChEMBL DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) B 5.66 pIC50 2165 nM IC50 DrugMatrix in vitro pharmacology data
Cav1.2/Voltage-gated L-type calcium channel alpha-1C subunit in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3762] [GtoPdb: 529] [UniProtKB: P22002]
ChEMBL Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in rat myocyte F 5.46 pIC50 3500 nM IC50 IC50 data for the L-type calcium channel extracted from a set of literature articles
Kv1.8 in Human [GtoPdb: 545] [UniProtKB: Q16322]
GtoPdb - - 6.3 pIC50 - - - Am J Physiol Renal Physiol (2000) 278: F1013-21 [PMID:10836990]

ChEMBL data shown on this page come from version 34:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]